Literature DB >> 11272701

Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations.

L Wang1, Y Duan, P Stouten, G V De Lucca, R M Klabe, P A Kollman.   

Abstract

The cyclic urea inhibitors of HIV-1 protease generally have two hydroxyl groups on the seven-membered ring. In this study, free energy perturbation and continuum electrostatic calculations were used to study the contributions of the two hydroxyl groups to the binding affinity and solubility of a cyclic urea inhibitor DMP323. The results indicated that the inhibitor with one hydroxyl group has better binding affinity and solubility than the inhibitor with two hydroxyl groups. Therefore, removal of one hydroxyl group from DMP323 may help to improve the properties of DMP323. This is also likely to be true for other cyclic urea inhibitors. The study also illustrated the difficulty in accurate modeling of the binding affinities of HIV-1 protease inhibitors, which involves many possible protonation states of the two catalytic aspartic acids in the active site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272701     DOI: 10.1023/a:1008156222963

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  28 in total

1.  Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7.

Authors:  L T Chong; Y Duan; L Wang; I Massova; P A Kollman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 2.  The retroviral enzymes.

Authors:  R A Katz; A M Skalka
Journal:  Annu Rev Biochem       Date:  1994       Impact factor: 23.643

3.  Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations.

Authors:  T Hansson; J Aqvist
Journal:  Protein Eng       Date:  1995-11

Review 4.  Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Authors:  R M Hoetelmans; P L Meenhorst; J W Mulder; D M Burger; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1997-08

5.  A new method for predicting binding affinity in computer-aided drug design.

Authors:  J Aqvist; C Medina; J E Samuelsson
Journal:  Protein Eng       Date:  1994-03

6.  Decomposition of the free energy of a system in terms of specific interactions. Implications for theoretical and experimental studies.

Authors:  A E Mark; W F van Gunsteren
Journal:  J Mol Biol       Date:  1994-07-08       Impact factor: 5.469

Review 7.  Present status and future prospects for HIV therapies.

Authors:  M I Johnston; D F Hoth
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

Review 8.  How does HIV cause AIDS?

Authors:  R A Weiss
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

9.  Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach.

Authors:  M R Reddy; V N Viswanadhan; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

10.  Free energy calculations of the mutation of Ile96-->Ala in barnase: contributions to the difference in stability.

Authors:  Y C Sun; D L Veenstra; P A Kollman
Journal:  Protein Eng       Date:  1996-03
View more
  2 in total

Review 1.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design.

Authors:  Speranta Avram; I Svab; C Bologa; Maria-Luiza Flonta
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.